Kornimate/medical-research-clean huggingface dataset:
cognitive behavioral therapy (cbt) for ptsd in veterans with co-occurring suds

Conditions: PTSD; Substance Use Disorders

Summary: with this research, the investigators hope to learn if cognitive behavioral therapy (cbt) for posttraumatic stress disorder (ptsd) works in people who have both ptsd and problems with drugs or alcohol. in the past, people who had problems with drugs and alcohol were not given treatment for their ptsd. it was believed that ptsd treatment would get in the way of their drug and alcohol treatment. now the investigators believe that the ptsd symptoms may make it harder to avoid using drugs and alcohol, so the investigators want to see if people can get treatment for both problems at the same time. one hundred-sixty veterans from 3 sites who have both ptsd and substance use disorders will be in the study. in order to know if the ptsd treatment is helpful, half of the veterans in this study will receive ptsd treatment and half will continue to get their usual mental health and/or substance abuse treatment. who gets which treatment will be decided by a random process. the investigators will then compare the 2 groups to see if there are differences in their ptsd symptoms.

a randomized clinical trial to evaluate the effectiveness of a relatively simple, manual-guided cognitive behavioral therapy (cbt) for ptsd in patients with substance use disorders (suds). one hundred sixty outpatients with comorbid ptsd and suds from three va facilities will be randomly assigned to receive either cbt for ptsd in conjunction with standard treatment as usual (tau) (n = 80) or tau only (n = 80).

Eligibility criteria:
inclusion criteria: * at least age 18. * current sud diagnosis. * score of at least 45 on caps. * must speak english. * must agree to be taped. exclusion criteria: * acute psychotic symptoms, if not well connected with appropriate mental health services. * severe suicidality. * individuals with unstable medical or legal situations that would make completion of the study highly unlikely.

Keywords: ptsd substance use disorders
an evaluation of pdi-320 in comparison to its monads in adults with rosacea

Conditions: Rosacea

Summary: this 4-arm phase 2 vehicle-controlled study is designed to assess the safety and efficacy of pdi-320, and the individual components, in adult subjects with rosacea.


Eligibility criteria:
inclusion criteria: * subject has moderate to severe papulopustular rosacea and at least mild erythema and mild telangiectasia. * subject is willing and able to apply the test article(s) as directed, comply with study instructions and commit to all follow-up visits for the duration of the study. * if subject is a woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control for the duration of the study. exclusion criteria: * subject is pregnant, lactating or is planning to become pregnant during the study. * subject has any other active dermatological condition on the face that may interfere with the conduct of the study. * subject has used systemic immunosuppressants within 30 days prior to study start. * subject has used systemic retinoids within 6 months prior to study start. * subject has used any topical rosacea therapy within 14 days prior to study start. * subject has had laser or light therapy on the face within 3 months of study start. * subject is currently enrolled in an investigational drug or device study. * subject has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article. * subject has used vasodilators or adrenergic blocking agents within 6 weeks of study start (except subjects on stable dose for greater than 3 months). * subject has active ocular rosacea and/or blepharitis/meibomianitis requiring treatment by an ophthalmologist. * subject has previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics or use of the components of pdi-320.

Keywords: precision pdi-320 foam
cervical/thoracic neuromodulation and nociceptive processing

Conditions: Nociceptive Pain

Summary: several studies have demonstrated that direct currents delivered through the skin at the level of the low-thoracic spinal cord can influence spinal cord function. in human volunteers, anodal low-thoracic transcutaneous spinal direct current stimulation (tsdcs) alters spinal processing of nociceptive inputs. whether cervical tsdcs is able to do the same is less well known. in this double-blinded, sham-controlled and cross-over trial, the investigators will compare the effects on the nociceptive processing of healthy volunteers of cervical and low-thoracic tsdcs.

the investigators will compare the effects on the nociceptive processing of healthy volunteers of cervical and low-thoracic tsdcs. this study will be a double-blinded, sham-controlled, cross-over trial. each participant will undergo three experimental sessions (anodal cervical tsdcs and sham thoracic tsdcs vs. sham cervical tsdcs and anodal thoracic tsdcs vs. sham cervical tsdcs and sham thoracic tsdcs), separated by at least one week.

Eligibility criteria:
inclusion criteria: healthy young adults exclusion criteria: * known medical conditions (e.g., diabetes, neuropathy, psychiatric disorders, seizure, migraine, pacemaker or other implanted medical devices...) * use of any medication (except contraception)

Keywords: tsdcs non-invasive neuromodulation healthy volunteers
a study to investigate arbaclofen er tablets for the treatment of spasticity in patients with multiple sclerosis

Conditions: Spasticity

Summary: this is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral arbaclofen er tablets in ms patients with spasticity. arbaclofen er will be compared with placebo.

this is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral arbaclofen er tablets (80 mg/day) in ms patients with spasticity. arbaclofen er will be compared with placebo. the treatment groups will be randomized in a 1:1 ratio. there will be a 49-day dose escalation period, followed by a 84-day maintenance treatment period, followed by a 21-day taper period.

Eligibility criteria:
inclusion criteria: * subjects 18 to 65 years of age, inclusive * an established diagnosis per mcdonald criteria (polman et al 2011) of ms (either rr or sp course) that manifests a documented history of spasticity for at least 6 months prior to screening * spasticity due to ms as shown by a tnmas-mal score ≥ 2 * expanded disability status scale (edss) score greater than or equal to (≥) 3.0 and less than or equal to (≤) 7.0 * absence of infections, peripheral vascular disease, painful contractures, advanced arthritis, or other conditions that hinder evaluation of joint movement * use of a medically highly effective form of birth control (see section 7.8) during the study and for 3 months thereafter for women of child-bearing potential (including female subjects and female partners of non-sterile male subjects) * willing to sign the informed consent form (icf) exclusion criteria: * any concomitant disease or disorder that has symptoms of spasticity or that may influence the subject's level of spasticity * in the opinion of the investigator, the patient is unable to rate their level of spasticity or distinguish it from other ms symptoms * concomitant use of medications that would potentially interfere with the actions of the study medication or outcome variables * pregnancy, lactation, or planned pregnancy during the course of the study and for 3 months after the final study visit * current significant cognitive deficit, severe or untreated anxiety, severe or untreated depression * current malignancy or history of malignancy that has not been in remission for more than 5 years, except effectively treated basal cell skin carcinoma * any other significant disease, disorder, or significant laboratory finding which, in the opinion of the investigator, puts the subject at risk because of participation, influences the result of the study, or affects the subject's ability to participate
monitoring sedentary behavior and light physical activity in patients with stroke

Conditions: Stroke, Acute; Behavior; Physical Inactivity; Sedentary Behavior

Summary: this randomized control trial (rct) aims to test the effect of a 12 weeks tailored behavioral intervention on stroke survivors living in the community and compare the results to a control group of stroke survivors participating in standard care. the intervention's purpose is to lower the time spend with sedentary behavior and raise the level of physical activity in stroke survivors throughout their everyday life. the intervention contains two motivational interviews with a focus on goal setting, action planning, motivation, fatigue management, and general information on life after stroke. the primary outcome for behavior change is objectively measured physical activity using an activity tracker (activpal4 micro) and secondary glycohemoglobin and changes in quality of life.


Eligibility criteria:
inclusion criteria: * verified ischemic stroke or intracerebral hemorrhage * modified rankin score (mrs) 1-3 at discharge * discharged with at rehabilitation plan within 1-14 hospitalization days * able to ambulate independently * speak and understand danish exclusion criteria: * aphasia * unable to give informed consent * unable to ambulate independently * mental illness * other co-morbidity like terminal cancer.
association of oral lichen planus and thyroid disease

Conditions: Oral Lichen Planus; Thyroid Diseases

Summary: thyroid disease is a common endocrine disorder. oral lichen planus (olp) is a chronic autoimmune disease that occurs on the oral mucosa in 1-2% of the general population.the purpose of this study was to determine whether there is an association between thyroid disease and oral planus lichen in the population of our patients. in the last few years, a couple of studies have been published in the world literature that have studied the possible association of these diagnoses in different populations. most of the results showed a higher prevalence of thyroid disease in the population of lichen patients, compared with patients without lichen, although some results are contradictory. some authors believe that the onset of olp precedes thyroid dysfunction. in the population of croatian patients with lichen, no research has been done to study the possible connection between these two diseases. the obtained results could help clarify whether there is a connection between these two diagnoses in the population of our lichen patients and enable earlier detection of patients with thyroid hypofunction.


Eligibility criteria:
inclusion criteria: * for test group: female patients of the department of oral medicine school of dental medicine university of zagreb with clinically and histopathologically confirmed oral lichen planus * for control group: female patients of the department of oral medicine school of dental medicine university of zagreb, without oral lichen planus or other immune disorders; age matched to test group exclusion criteria: * male patients; female patients with immune disorders; female patients which are not age-matched to test group

Keywords: oral lichen planus thyroid diseases
procalcitonin and brain natriuretic peptides in patients with chronic kidney disease.

Conditions: Kidney Failure, Chronic

Summary: the study is being conducted to determine if the blood test brain natriuretic protein (bnp) can demonstrate the presence of extra fluid in patients with chronic kidney disease treated by hemodialysis. it will also try to determine the blood test procalcitonin (pct) can help identify the cause of the fever, specifically if a fever is caused by a bacterial infection. it will also evaluate whether new blood tests in the future (such as dna, rna, metabolite, and protein based tests) can be developed to help predict other complications in patients with chronic kidney disease treated by hemodialysis.

the study has three purposes: 1. to establish a procalcitonin (pct) algorithm to assist in the identification of bacterial infection in patients with fever and chronic kidney disease (ckd) being treated by hemodialysis; 2. to establish an algorithm to assist clinicians in distinguishing infection from fluid overload in patients with ckd treated by hemodialysis with shortness of breath using pct and brain natriuretic peptide (bnp); 3. to allow for evaluation of new tests, such as dna, rna, metabolite, and protein based tests, which might prove useful in the evaluation of clinical complications encountered by patients with chronic kidney disease treated by hemodialysis including infections and fluid overload. baseline visit: 1. review of medical and medication history 2. a physical exam and routine clinical laboratory tests (hematology and chemistry) will be performed. 3. pct and bnp levels will be measured twice prior to hemodialysis (hd) treatment to establish baseline levels. 4. optional: if the subject consent, samples will be obtained for genetic tests (dna, rna, metabolite and proteins) for new tests to be developed in the future. follow up: 1. a physical exam, routine clinical laboratory tests (hematology and chemistry) and medical and medication review will be obtained monthly. if a subject develops signs of infection or shortness of breath during the course of the study, additional research blood samples for procalcitonin, brain natriuretic peptide, and for genetic testing (optional) will be obtained as follows: 1. for patients with suspected infection, pct levels will be drawn at the time of suspected infection and again at the start of the next hd treatment. 2. for patients with shortness of breath, pct and bnp levels will be drawn at the time of the complaint and again at the start of the next hd treatment.

Eligibility criteria:
inclusion criteria: 1. males and females, 18 years and older. 2. subject is receiving hemodialysis. 3. able to provide informed consent. exclusion criteria: 1. subject is unable or unwilling to provide informed consent.
blood test (guardant shield™) for screening of colorectal cancer in underserved patients

Conditions: Colorectal Carcinoma

Summary: this clinical trial evaluates the use of a blood test (guardant shield™) for colorectal cancer screening. colorectal cancer is the third leading cancer and cause of death in the united states. screening may help doctors find colorectal cancer early when it is easier to treat yet nearly a third of all people eligible for screening have never had a screening test performed. currently, doctors use a stool- based test such as the fecal immunochemical test (fit) and visual tests such as a colonoscopy. blood based testing such as guardant shield™, may provide a quick and effective way to screen patients that are hard to reach or with limited access (underserved).

primary objectives: i. recruit women age 45 years and older who are in need of colorectal cancer screening from minority and underserved populations via a community mammography van. ii. obtain data regarding knowledge, attitudes and beliefs about colorectal cancer screening. outline: participants undergo blood specimen collection and complete survey on study. participants may optionally undergo standard of care fit testing on study.

Eligibility criteria:
inclusion criteria: * women aged 45 years of age and older who are in need of colorectal screening * do not have a history of cancer * able to read and understand english * have a provider to receive the results of the test and who will follow-up test results * able to provide informed consent
ropivacaine 0,2% plus dexamethasone versus ropivacaine 0,2% plus placebo in modified pectoral block

Conditions: Effect of Drugs; Breast Pain; Anesthesia, Local

Summary: to find out if dexamethasone used as adjuvant to ropivacaine, a long-lasting local anesthetic, prolongs the duration of modified pectoral nerve block in women undergoing breast surgery.

breast surgeries are one of the most common forms of surgery conducted in hospitals, and even relatively minor interventions can be associated with significant postoperative pain. the most common surgical procedure for breast cancer is modified radical mastectomy, which means removing a generous amount of skin and the entire breast with axillary evacuation. according to the literature, up to 50% of breast surgery patients experience severe acute postoperative pain, with 10-40% breast cancer patients experiencing pain a year or more after surgery. poorly controlled postoperative pain has negative physiological and psychological consequences. furthermore, effective acute pain control preserves immune function both by suppressing surgical stress response and decreasing the need for general anesthetics and opioids in the perioperative period. the ultrasound-guided modified, pectoral nerve block is a frequently used, easy, and reliable technique to provide complete analgesia during and after breast surgery. a major limitation to its use for postoperative analgesia is that the analgesic effect lasts only a few hours, after which moderate to severe pain at the surgical site may result in the need for alternative analgesic therapy. several adjuvants have been used to prolong the analgesic duration of peripheral nerve block, including perineural/interfascial or intravenous dexamethasone. our aim is to explore the efficacy of 8 mg dexamethasone added to us-guided modified pectoral nerve block on postoperative pain in patients undergoing major breast surgery.

Eligibility criteria:
inclusion criteria: * female gender * a american society of anesthesiologists (asa) score of 1 or 2 * weight: body mass index (bmi) 18 - 35 kg/m2 * informed consent * elective, unilaterale breast surgery exclusion criteria: * bleeding disorders * any known allergy to the medication * diabetes mellitus * any disease that leads to alterations in the corticosteroid physiology * drug-dependency * bmi \ 35 * systemic infections * psychiatric diseases, that are associated with an alteration in the perception of pain * tumor spread at the site of injection * inflammation at the site of injection * pregnancy
invite study: invasive instrumentation in trauma patients in the shock room

Conditions: Multiple Trauma

Summary: this study is an online survey asking for invasive instrumention in trauma patients of an emergency department

the invite study is an online survey for medical doctors asking for invasive instrumention (e.g., arterial line, entral venous line, etc.) in trauma patients of an emergency department

Eligibility criteria:
inclusion criteria: * patients with multiple trauma * treated in the emrgency department exclusion criteria: * none

Keywords: polytrauma, emergency medicine
relation between atherogenic index of covid-19 and upcoming cardiac morbidity and mortality in non-cardiac patients

Conditions: COVID-19

Summary: plasma lipids levels were estimated and the atherogenic index of plasma (aip) was computed in 302 covid confirmed patients. patients were evaluated using the covid-gram (cg) critical illness score and during a hospital stay the rates of admission to intensive care unit (icu), development of cardiac insults, and need for admission to cardiac icu (ccu) and its outcome were determined.

all patients were admitted to the quarantine department at tanta university hospital and quarantine hospitals at al-gharbia governorate with a diagnosis of sers-cov-19 infection that was confirmed by having positive nasopharyngeal swab for sars-cov-2 using reverse transcriptase-polymerase chain reaction (rt-pcr). the study protocol was approved by the local ethical committee according to instructions of the ministry of health and written informed consents were signed by all enrolled patients or their nearest relative. using the strict personal protective equipment, patients were clinically examined for collection of the demographic data age, sex, weight and height, history taking especially past and/or present history of diabetes mellitus (dm), hypertension, cardiac diseases, hypercoagulability events, chest, liver or kidney diseases or endocrinopathy. bmi was calculated in kg/m2 as weight (kg)/height (m2) (14) and was graded according to the guidelines of who (15). the chest was examined clinically and ct imaging was performed to assess the disease severity. clinical parameters 1. covid-19 disease severity grading 2. covid-gram critical illness risk score 3. atherogenic index of plasma (aip) laboratory investigations a- routine lab investigations included estimation of random blood glucose, complete blood count and serum levels of urea, creatinine, liver enzymes, and total and direct bilirubin b- investigations for evaluation of sars-cov-2 infection severity including estimation of serum c-reactive protein, interleukin-6, lactate dehydrogenase, d-dimer levels. c- estimation of a plasma lipid profile

Eligibility criteria:
inclusion criteria: * only non-cardiac patients with confirmed covid-19 disease who had mild-to-severe covid disease according to the guidelines of the national institutes of health admitted to quarantine hospitals and free of exclusion criteria were enrolled in the study. patients were categorized according to disease severity into mild, moderate, and severe. exclusion criteria: * patients presented by covid disease of critical severity that necessitated admission to icu at time of hospital attendance, admission to icu for any other indication, presence of a history of cardiac diseases, previous cardiothoracic or chest surgery for any indication, bmi of ≥35 kg/m2, presence of endocrinopathy, preexisting autoimmune diseases, current maintenance on immunosuppressive drugs, malignancy elsewhere in body organs, refusal to sign the written consent to receive the study protocol or death just on admission or before completion of the diagnostic protocol.
reversal of ventricular remodeling with toprol-xl

Conditions: Heart Failure, Congestive

Summary: the purpose of this study is to determine whether treatment with toprol-xl for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.


Eligibility criteria:
inclusion criteria: * diagnosis of stable asymptomatic heart failure. * documented ejection fraction less than 0.40. * must be able to comply with all study procedures. exclusion criteria: * taken b-blocker therapy for longer than 1 week within 6 months prior to randomization. * have heart problems that would not allow b-blocker therapy. * receiving b-blockers therapy for any medical reason including topical b-blockers that might cause systemic absorption (e.g., glaucoma). * undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty. * have certain heart diseases. * pregnant or breast feeding. * unlikely to survive.